NuvoAir is a technology company.
NuvoAir has raised $12.0M across 1 funding round.
NuvoAir has raised $12.0M in total across 1 funding round.
NuvoAir has raised $12.0M in total across 1 funding round.
NuvoAir's investors include Albion VC, Amino Collective, Ananda Impact Ventures, LocalGlobe, Webtalk Ltd.
NuvoAir is a digital health technology company specializing in respiratory care through virtual patient engagement and advanced remote monitoring solutions. It builds connected devices and software platforms, including Bluetooth-enabled spirometers and inhaler sensors, to serve patients with chronic respiratory diseases such as COPD, asthma, and chronic heart failure. NuvoAir’s technology empowers patients and clinicians with real-time data and AI-driven insights to improve diagnosis, treatment, and management of respiratory conditions, reducing urgent care visits by nearly 40% and enhancing patient quality of life[1][2][3].
Founded in 2016 in Stockholm and now headquartered in Boston, NuvoAir was inspired by the founder’s personal experience with childhood asthma. The company quickly gained traction by integrating human-led care with disruptive technology, expanding into clinical trial solutions and virtual care services. Key milestones include FDA clearance for home spirometry devices and raising $12 million in Series A funding in 2021, which accelerated its growth and innovation in AI-powered respiratory health monitoring[1][3][4].
NuvoAir rides the growing trend of digital health and remote patient monitoring, which has become critical due to the COVID-19 pandemic and the increasing prevalence of chronic respiratory diseases worldwide. The timing aligns with healthcare’s shift toward virtual care, AI integration, and patient empowerment, supported by rising demand for cost-effective, accessible chronic disease management. NuvoAir’s solutions influence the broader ecosystem by enabling decentralized clinical trials and enhancing collaboration between patients, clinicians, and pharma companies[2][4][5][6].
NuvoAir is positioned to expand its footprint in the US and global markets by advancing AI-native healthcare solutions and integrating with electronic medical records for population health management. Future trends shaping its journey include increased adoption of virtual care, AI-driven diagnostics, and personalized medicine. As it scales, NuvoAir’s influence may grow beyond respiratory care to broader chronic disease management, driving improved outcomes and operational efficiencies in healthcare systems worldwide[4][6][7].
NuvoAir has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $12.0M Series A | Albion VC, Amino Collective, Ananda Impact Ventures, LocalGlobe, Webtalk Ltd |